Advertisement
Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg
Drug Metabolism and Disposition November 2001, 29 (11) 1480-1484;
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

CYP2B6 and CYP2C19 as the Major Enzymes Responsible for the Metabolism of Selegiline, a Drug Used in the Treatment of Parkinson's Disease, as Revealed from Experiments with Recombinant Enzymes

Mats Hidestrand, Mikael Oscarson, Jarmo S. Salonen, Leena Nyman, Olavi Pelkonen, Miia Turpeinen and Magnus Ingelman-Sundberg
Drug Metabolism and Disposition November 1, 2001, 29 (11) 1480-1484;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement